Anupam Rasayan Signs $300M LOI for EV Battery Chemicals

Anupam Rasayan, a specialty chemical manufacturer that makes complex ingredients for global agrochemical, pharma, and electronics companies, has signed a non-binding Letter of Intent with Basquevolt, a Spanish solid‑state lithium‑battery developer, to explore supplying a specialty chemical product worth $300 million over up to 10 years [announcement]. The LOI is a fresh signal of the company’s deepening push into EV‑battery chemicals — a segment where its standalone revenue has already tripled from ₹97 crore in FY22 to ₹305 crore in FY26 — but the agreement is early‑stage: any supply is contingent on product development and a definitive contract that does not yet exist [announcement].

What the LOI Covers — and What It Doesn’t

The LOI is a preliminary, non‑binding intent to negotiate a potential supply agreement for a single, unspecified specialty chemical. The cumulative revenue is pegged at $300 million over up to 10 years, but the company has not disclosed the chemical, per‑unit pricing, volume ramp, or a timeline for completing product development [announcement].

The two conditions that must be met are clear: successful product development and the negotiation of a binding definitive supply agreement — neither is assured [announcement]. No target date for either milestone has been given.

A Strategic Pattern That Is Now Well‑Rehearsed

This is not the company’s first battery‑chemical LOI. In Q4FY25 it signed a 5‑year, ₹3,000 crore LOI with Elementium, a US entity, with commercialization expected in FY27 . Across its business, Anupam Rasayan has signed at least 12 non‑binding LOIs with multinational customers since FY22; seven have since begun commercialization, while five are on track for FY27 or FY28 . That track record suggests management is comfortable using LOIs to secure a seat in customers’ supply‑chain planning before it commits capital to dedicated capacity.

The Basquevolt LOI falls squarely within the Performance Materials vertical that management has flagged as a key growth driver. In FY26, that vertical — spanning polymers, electronic chemicals, semiconductor materials, and EV battery chemicals — contributed 18% of standalone revenue, up from 13% in FY25 . Management has stated that Pharma and Performance Materials are expected to grow faster than agrochemicals over the next three to five years .

Financial Capacity to Execute, Without Immediate Capex

If the LOI turns into a firm contract, the company likely has existing capacity headroom. In May 2026, CFO Amit Khurana noted that all plants from the last capex cycle are now commercialized and that “we are not envisaging any major capex in near future as current capacity is enough to take care of the near‑term growth” . Deputy CFO Vishal Thakkar estimated that the standalone gross block can support peak revenue of about ₹3,500 crore — against FY26 standalone revenue of ₹1,676 crore .

The balance sheet has room to add debt if needed. Consolidated gross debt stood at ₹1,815 crore at March 2026, with net debt of ₹1,437 crore and a debt‑to‑equity ratio of 0.39x . Operating cash flow hit a record ₹334 crore in FY26, swinging from a negative ₹30 crore the year before . When the company recently funded the Bliss GVS Pharma acquisition, it used a mix of ₹300 crore via non‑convertible debentures and non‑voting equity instruments, and management described the resulting pro‑forma leverage as comfortable relative to expected EBITDA . On a pro‑forma basis — combining Anupam, Tanfac, Jayhawk, and Bliss — the company would have annual revenue of over ₹4,000 crore and EBITDA of about ₹834 crore, providing substantial debt‑servicing capacity .

Performance Materials share for FY25 from ; FY26 from .

The margin compression visible in FY26 — EBITDA margin fell from 28.7% to 23.0%, the lowest in at least five years — reflects the cost of integrating acquisitions (Jayhawk, Tanfac) and a shift in product mix as new molecules ramped up . Revenue, however, grew 65% year‑on‑year, driven by both acquisitions and the commercialization of earlier LOIs .

What Happens Next

The company has not specified a date for completing product development or signing a definitive agreement. The next concrete milestone will be either an update on the LOI’s progress or the signing of a binding supply contract. Until then, the LOI remains a directional signal of the company’s push into EV battery chemicals, backed by a pattern of converting such preliminary accords into commercial revenue — but carrying the standard execution risk of any early‑stage chemical‑development agreement.

---

What the LOI Covers — and What It Doesn’t

A Strategic Pattern That Is Now Well‑Rehearsed

Financial Capacity to Execute, Without Immediate Capex

What Happens Next

Sources